RxDoctor Payments Data

Andrea Rudolph

Acute Care · Los Angeles, CANPI 1811109986

Payments from drug & device makers

$2,888in general payments, 2019–2025

Across 141 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$665
  • AbbVie$508
  • Amgen$276
  • Lilly USA, LLC$207
  • Bayer$195
  • AstraZeneca$184
  • plus $853 from 14 others

What the payments were for

  • Food & beverage$2,888100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,888 in reported general payments places this provider in the 85th percentile of 1,153 acute care providers in California.

See all acute care providers in California

Medicare billing

Part B allowed, 2024
$14,231
Medicare patients
75
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin36$42,497
OzempicSemaglutide24$23,165
TrulicityDulaglutide13$11,549
SymbicortBudesonide/Formoterol Fumarate21$5,014
Tresiba Flextouch U-100Insulin Degludec11$4,960
Albuterol Sulfate HfaAlbuterol Sulfate50$1,780
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,516
Doxepin Hcl11$1,320
BreynaBudesonide/Formoterol Fumarate13$987
ValacyclovirValacyclovir Hcl13$922
Atorvastatin Calcium139$809
Gabapentin37$744
Omeprazole72$654
Diclofenac Sodium30$653
Azelastine Hcl13$412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$138$42,49736 claims
Novo NordiskOzempic$665$23,16524 claims
Lilly USA, LLCTrulicity$207$11,54913 claims
AstraZenecaSymbicort$184$5,01421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,153 acute care providers in California.

Other acute care in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →